Tocilizumab is able to attenuate the levels of IFN‐γ, IL10, and IL2, and treat refractory hemophagocytic lymphohistiocytosis (HLH) with expansion of cytotoxic T and NK cells.144. The gene discussed is IL10; the disease is hemophagocytic syndrome.